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Ewing sarcoma is a bone-associated malignancy of children and adolescents 
caused by EWS/FLI, an oncogenic transcription factor encoded by a chromosomal 
translocation. EWS/FLI causes massive transcriptional dysregulation. A critical 
upregulated target, NKX2-2, is a homeodomain transcription factor required for Ewing 
sarcomagenesis; however, its specific role in this disease is unknown. We addressed this 
question using a twofold approach. First, using RNA sequencing, we found that NKX2-2 
represses genes important for cell adhesion and ECM organization. We also show that it 
inhibits mesenchymal features of Ewing sarcoma cells: actin stress fiber organization, 
focal adhesion assembly, cell spreading—phenocopying EWS/FLI knockdown. NKX2-2-
depleted cells also display increased cell adhesion and migration. Finally, we show that 
NKX2-2 and ZEB2 mediate anti-mesenchymalization and anti-epithelialization 
programs, respectively, in Ewing sarcoma to keep cells in a partially undifferentiated 
state. Second, we show that NKX2.2 binds MTG16 in an interaction that is disrupted by 
Notch. Presumably, these proteins comprise a repressor complex given the proper 
cellular context. Furthermore, NKX2.2 is capable of oligomerization; interestingly, both 
heterotypic and homotypic interactions are mediated by the transcriptional activation 
domain of NKX2.2. While the biological significance of the NKX2.2-MTG16 interaction 
is currently unknown, we propose that investigating this complex may be tractable in 
pancreatic β-islet cells. Importantly, defining the transcriptional targets and elucidating 
the molecular interactions of critical transcription factors in Ewing sarcoma, as well as in 
other cancers, may more fully define their function. 
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Ewing sarcoma is a bone-associated malignancy that affects mostly children and 
young adults that was first described by James Ewing as a diffuse endothelioma of bone 
in 1921 [1]. It is a rare cancer, occurring at a rate of 3 per million per year in the United 
States [2]. Though usually occurring in bone, it arises in soft tissue as well, and is 
frequently described as a small, round, blue-cell tumor (SRBCT). Patient survival has 
steadily improved over the past few decades. Five- and ten-year survival rates currently 
stand at 68% and 63% for localized disease, and 39% and 32% for metastatic disease, 
respectively, according to Surveillance, Epidemiology, and End Results (SEER) data 
from 1973 through 2004 [2]. SEER data also indicate that the five-year conditional 
survival for localized disease increases with time: 72.9% at diagnosis to 91.4% five years 
after diagnosis. Predictably, these numbers are lower for metastatic disease, at 31.7% and 
83.6%, respectively [3]. Furthermore, using California Cancer Registry data from 1989 to 
2007, several factors that are correlated with significantly poorer outcome, such as large 
tumor size, pelvic involvement, lack of surgery, Hispanic ethnicity, and low 
socioeconomic status, were identified [4]. Thus, even if outcome has significantly 
advanced, there is still a lot that can be done, especially for patients who present with 
metastases at diagnosis. There is currently no molecularly targeted strategy available to 
treat Ewing sarcoma. A specific drug would potentially raise patient survival even 
further, while avoiding the undesirable side effects of the cytotoxic therapies presently 
being utilized. 
Ewing sarcoma is characterized by a requisite reciprocal translocation between a 
FET (FUS, EWSR1, TAF15) gene and a member of the ETS (E26 transformation specific) 
family of transcription factors (reviewed in [5]). t(11;22)(q24;q12), the archetypal and by 
far the most common translocation (found in 85% of all Ewing sarcomas), fuses the 
transcriptional regulatory domain of EWS to the DNA binding domain of FLI [6-8]. 
EWS/FLI causes massive transcriptional dysregulation in Ewing sarcoma [9-12]. Though 
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recent genomic sequencing studies of Ewing tumor samples and established cell lines 
identified a few recurrent mutations (STAG2, CDKN2A, and TP53), the majority of 
tumors are—with the exception of the EWS/FLI lesion itself—genetically quiet [13-15]. In 
the absence of other cooperating mutations, it is thought that the different arms of tumor 
pathogenesis in Ewing sarcoma are controlled exclusively by EWS/FLI [16]. 
Various EWS/FLI transcriptional targets have been identified previously [9, 10, 
12, 17-27]. EWS/FLI is capable of directly activating targets by binding GGAA 
microsatellites [28, 29] and of directly repressing targets in a histone deacetylase 
(HDAC)-dependent fashion by binding an as yet uncharacterized consensus site [19]. 
Both activation and repression mechanisms require the recruitment of lysine-specific 
demethylase 1 (LSD1) [30]. We and others have shown that several of the identified 
EWS/FLI transcriptional targets are necessary for the transformed phenotype. 
Interestingly, a number of these targets are transcription factors themselves, implying 
that EWS/FLI may amplify its regulatory effects by causing subsequent waves of 
transcription. One of these EWS/FLI-upregulated transcription factors is NKX2-2 [9, 
31]. 
NKX2-2 belongs to a family of evolutionarily ancient homeobox-binding 
transcription factors [32, 33]. The Drosophila melanogaster ortholog vnd (ventral 
nervous system defective) was identified in the late 1970s and early 1980s as a deletion 
of the tip of the fly X chromosome. Deletion of or mutations in this region are lethal, and 
examination of fly embryos revealed a near-absence of a ventral nervous system [34-36]. 
The gene responsible for the defect was isolated and sequenced in 1989, along with three 
other related genes, and were collectively named the NK homeobox genes, after the 
authors Marshall Nirenberg and Yongsok Kim [37]. The primary protein structure of 
human NKX2.2 has since been defined. (Nomenclature of human genes dictates using 
“NKX2-2” for the gene and “NKX2.2” for protein.) It has four important domains; from 
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the N to the C termini, they lie: tinman (TN), homeodomain (HD), specific domain (SD), 
and transcriptional activation domain (TAD) (Fig. 3.1) [38-40]. Sequencing of the gene 
and of the protein it encodes then allowed the dissection of the physiological function of 
NKX2-2 in development. 
A host of studies using mouse models have defined the role of Nkx2.2 in 
mammalian development. While heterozygous littermates survive to adulthood, mice 
with constitutive homozygous deletion of Nkx2.2 die shortly after birth due to a complete 
lack of functional, insulin-producing β-cells and a reduced number of glucagon-
producing α-cells and pancreatic polypeptide (PP)-producing γ-cells, resulting in severe 
hyperglycemia. In this model, most markers of β-islet differentiation are lost, suggesting 
that the loss of Nkx2.2 traps β-cells in a partially differentiated state [41]. Interestingly, 
several transcription factors were demonstrated to functionally bind the promoter of the 
insulin gene in vivo: Nkx2.2; Pax6, with which Nkx2.2 defines the dorsoventral axis of 
the developing neural tube; Pdx1, a homeobox factor and pancreas-specific marker; and 
Beta2 [42]. Furthermore, using Nkx2.2-HD fusions with the Engrailed repressor or VP16 
activator, it was demonstrated that, while Nkx2.2-repressor activity is sufficient to 
specify α-cells and a reduced number of β-cells, Nkx2.2-activator activity seems to be 
required for full β-cell maturation. In addition, the interaction of Nkx2.2 with Grg3, a 
Groucho/transducin-like enhancer of split (Gro/TLE) family member that is highly 
expressed in the embryonic pancreas, is lost when TN is deleted [43]. To further 
investigate the role of the NKX2.2 transcriptional repressor activity, Papizan and 
colleagues demonstrated that a homozygous TN mutation disrupts Grg3 interaction and 
β-cell specification, causes hyperglycemia, and induces ectopic expression of the 
Aristaless homeobox (Arx) gene in β-cells, leading to β-to-α-cell reprogramming [44]. 
Somewhat relatedly, Nkx2.2 is required for the development of enteroendocrine cells in 
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the intestine, though it is dispensable for the development of enterocytes, paneth cells, 
and goblet cells [45]. 
In the realm of central nervous system (CNS) development, the related genes 
Nkx2.2, Nkx2.9, and Nkx6.1 in concert control the differentiation of neural progenitors 
that give rise to motor neurons and interneurons [46-50]. In particular, while Nkx2.2 is 
not required for the establishment of progenitor cell populations in the ventral neural 
tube—due to possible redundancy with Nkx2.9—it is required for the maintenance of V3 
interneurons. Moreover, Nkx2.2 suppresses the development of somatic motor neurons 
[46]. Lastly, Nkx2.2 also regulates oligodendrocyte differentiation [51, 52]. 
In Ewing sarcoma, NKX2-2 was identified as a top EWS/FLI-activated gene in 
the cell line A673 in early microarray transcriptional profiling studies [9]. Smith and 
colleagues demonstrated that depletion of NKX2-2, while not adversely affecting cell 
growth in culture, completely ablated the ability of Ewing sarcoma cells to form colonies 
in soft agar; anchorage-independent growth is a measure of transformation. This 
phenotype is rescued by expressing an RNAi-resistant NKX2-2 cDNA, demonstrating 
that the loss of transformation is specifically attributable to the loss of NKX2-2. 
Similarly, NKX2-2 knockdown cells were unable to form tumors in a xenograft mouse 
model. Tumors eventually grew in some mice, but it was demonstrated that these 
originated from cells that had lost the knockdown and started to re-express NKX2-2. 
Collectively, these data show that NKX2-2 is absolutely required for the maintenance of 
transformation in Ewing sarcoma. However, re-expression of NKX2-2 upon EWS/FLI 
knockdown did not rescue transformation, demonstrating that NKX2-2 is insufficient for 
EWS/FLI-mediated transformation and suggesting that many other transcriptional 
targets of EWS/FLI are jointly responsible for the transformed phenotype [9]. 
The regulation of NKX2-2 by EWS/FLI is an area of active research. In the 
developing neural tube, a gradient of Hedgehog (Hh) signal activates the Gli family of 
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transcription factors, which in turn activate Nkx2.2 [53-55]. Since EWS/FLI also 
upregulates GLI1, albeit in a Hh-independent fashion [18, 20, 23], one possibility is that 
the GLI1-NKX2-2 regulation node is conserved in Ewing sarcoma [22]. Furthermore, it 
has been demonstrated that GLI1 is a direct transcriptional target of EWS/FLI, further 
suggesting that NKX2.2 upregulation by EWS/FLI occurs indirectly [22]. However, 
recent ChIP-seq data revealed an EWS/FLI-bound microsatellite region ~40 kb 
upstream of the NKX2-2 transcription start that may serve as an enhancer element, 
suggesting that EWS/FLI directly activates NKX2-2 ([56]; Jason Tanner et al., 
unpublished data). Further studies need to be performed to determine whether this 
microsatellite facilitates active transcription of the NKX2-2 gene in Ewing sarcoma. 
The work of Smith et al. in the Lessnick Lab paved the way for investigating 
NKX2-2 function in Ewing sarcoma. In a subsequent study in our lab, Owen et al. 
performed NKX2-2 microarray transcriptional profiling in A673 cells [31]. It was found 
that NKX2-2 controlled a small but significant subset of EWS/FLI-repressed genes. 
Moreover, it was shown that enforced expression of AES (amino enhancer of split), a 
dominant-negative Gro/TLE protein, or treatment with the pan-HDAC inhibitor 
vorinostat, abrogated transformation in a soft agar assay. This suggested that Gro/TLE 
and HDAC function are essential to transformation, as could be expected if these co-
repressors are recruited by NKX2.2 to its target loci. Strikingly, treatment of Ewing 
sarcoma cells with vorinostat completely reversed the NKX2-2 transcriptional profile, 
suggesting that indeed NKX2-2 represses its targets via a histone deacetylation-
dependent mechanism [31]. 
EWS/FLI controls the regulation of multiple genes with vastly different 
functions. Transcriptional profiles generated through microarray and RNA-seq, as well 
as DAVID gene ontology and KEGG pathway analyses, reveal that EWS/FLI represses 
genes that are important for focal adhesion (FA), extracellular matrix (ECM) receptor 
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function, and regulation of actin cytoskeleton, among others [30, 31, 57]. Chaturvedi et 
al. showed that, strikingly, knockdown of EWS/FLI results in cells that assemble more 
FAs, form thicker and more organized actin stress fibers, and spread better on a 
fibronectin substrate, compared to control. Moreover, these EWS/FLI-depleted Ewing 
sarcoma cells also display reduced adhesion to substrate in vitro, reduced adhesion to 
lung parenchyma in vivo in a tail vein injection model, and dramatically increased 
migration in a scratch assay [58]. Some transcriptional targets of EWS/FLI that control 
mesenchymalization were also identified [57]. For instance, EWS/FLI represses zyxin, 
which stabilizes actin stress fibers, and α5 integrin, which attaches as a heterodimer with 
β1 integrin to fibronectin in the ECM. Individual re-expression of these genes results in 
manifestation of a subset of mesenchymal traits. Meanwhile, double re-expression of 
zyxin and α5 integrin is sufficient to capture the full complement of mesenchymal traits 
controlled by EWS/FLI and also reduces colony growth in soft agar, while having a 
negligible effect on the proliferation of cells in culture [57]. Taken together, these data 
suggest that EWS/FLI represses mesenchymal features of Ewing sarcoma [58]. 
More recently, the Lessnick Lab demonstrated that the zinc finger E-box-binding 
homeobox 2 (ZEB2) gene is expressed at high levels in Ewing sarcoma cell lines, human 
neural crest stem cells, and bone marrow-derived mesenchymal stem cells [59, 60]. 
ZEB2 RNA-seq transcriptional profiling using two independent siRNAs revealed that 
ZEB2 represses genes important in epithelial cell differentiation, actin binding, cell 
junctions, etc., suggesting that this transcription factor may repress epithelial features of 
Ewing sarcoma [60]. Indeed, when ZEB2 is depleted from Ewing sarcoma cells, they 
assume epithelial features: a cobblestone morphology with an actin ring structure 
around the cell periphery, and slower migration in a scratch assay compared to control 
knockdown cells. Moreover, enforced expression in Ewing sarcoma cells of a miR-200 
cluster, known to repress both ZEB2 and the related ZEB1, causes de-repression of the 
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epithelial genes keratin 8 and desmoplakin and reduces migration capacity compared to 
a miR control. Importantly, ZEB2 knockdown impairs the metastatic capacity of Ewing 
cells in an intratibial xenograft model. Collectively, these data show that ZEB2 represses 
epithelial features of Ewing sarcoma [60]. 
 These studies performed by our group and Mary Beckerle’s group again bring 
forth the question of the Ewing sarcoma cell-of-origin, which is yet to be definitively 
determined. Early work showed that enforced expression of EWS/FLI in heterologous 
cells had disparate results: soft agar colony growth and transformation in mouse 
embryonic fibroblasts [8] and p53-dependent growth arrest in primary human foreskin 
fibroblasts [61]. Because of the demonstrated differences in gene expression profiles 
between the Ewing sarcoma cell line A673 and the hitherto preferred EWS/FLI-
transduced NIH3T3 model [62], our lab and others moved to a system in which 
EWS/FLI was RNAi-depleted in Ewing cell lines [9, 10, 63].  
 Of the various potential cells-of-origin proposed, neural crest cells and 
mesenchymal stem cells (MSCs) have been the most favored [16]. Ewing tumor cells are 
known to express neuroectodermal markers and can be induced to display features of 
neural differentiation [64-66]. Enforced EWS/FLI expression in a rhabdomyosarcoma 
cell line results in a Ewing sarcoma-like morphology and induction of genes highly 
expressed in Ewing sarcoma and in the neural crest [67]. Likewise, transcriptional 
profiles of Ewing tumors and A673 cells cluster strongly with those from brain tissue and 
human vascular endothelial cells [68]. However, as had been pointed out before, these 
lines of evidence cannot distinguish between a neural crest origin and a model in which 
the EWS/FLI translocation occurs in a cell type permissive to the induction of neuronal 
features [21, 67, 68]. 
 The proposal that MSC is the Ewing sarcoma cell-of-origin is more recent. For 
example, both EWS/FLI and EWS/ERG blocked the differentiation of murine bone 
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marrow-derived stromal cells along the osteogenic and adipogenic pathways, two 
lineages arising from MSCs [69]. Viable SRBCTs are produced in murine primary bone-
derived cells grafted into immunocompetent mice [70] or in murine primary bone 
marrow-derived mesenchymal progenitor cells grafted into SCID mice [71]. Using a loss-
of-function approach, Tirode and colleagues demonstrated that EWS/FLI-depleted 
Ewing cells mimicked the transcriptional profile of MSCs and can be induced towards 
adipogenic differentiation, suggesting a mesenchymal origin [72]. Ectopic EWS/FLI 
expression in mesenchymal cells of the developing mouse limb bud gives rise to SRBCTs, 
but only with an accompanying p53 deletion [73]. To more accurately model Ewing 
sarcoma, Riggi and colleagues expressed EWS/FLI in human MSCs. However, while the 
gene expression of these derivative MSCs closely and specifically approached that of 
Ewing sarcoma, xenografts in immunocompromised mice failed to generate tumors [74]. 
Interestingly, the neural crest and MSC models may not be mutually exclusive; Ewing 
sarcoma initiation has been demonstrated both in human neural crest stem cells and the 
MSCs that derive from them [59, 75]. These key studies represent only a subset of the 
current literature; extensive reviews have previously been published [16, 76]. 
As a manner of summary, I offer here three reasons why studying Ewing sarcoma 
is vastly important. First, it is a devastating disease that affects children and adolescents. 
Although the overall outcome has risen, patients with metastatic or recurrent disease 
face very poor prognoses. Our goal in the Lessnick Lab is to understand the disease 
biology to aid in identifying therapeutically targetable genes or pathways. Such a directed 
treatment, while bettering patient survival, also will hopefully reduce adverse side effects 
of currently available nonspecific chemotherapeutics. The importance of this cannot be 
overstated in pediatric malignancies where young survivors look forward to many years 
of fruitful life after cancer. 
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Secondly, Ewing sarcoma is an important model for studying genomically silent 
malignancies. While cancers are generally driven by a primary genetic aberration, many 
of these co-opt secondary hits, usually the result of a mutation in p53 or another gene 
that compromises genetic stability, that are necessary for tumor maintenance and/or 
metastasis. The singularity of EWS/FLI as a genetic lesion that controls myriad aspects 
of oncogenesis is rare. In the absence of confounding cancer “engines,” Ewing sarcoma 
and its EWS/FLI “driver” are an excellent platform in which to study how transcriptional 
dysregulation can solely drive runaway cell proliferation, escape from cell death, drug 
resistance, and avoidance of terminal differentiation. 
Lastly, Ewing sarcoma is unique in that, until now, its cell-of-origin has yet to be 
definitively characterized. Correct identification of this permissive cell type will allow 
genetic models to be constructed; these, in turn, will aid in understanding basic biology 
and in testing of possible drug leads. Moreover, this difficulty has underscored the 
importance of cellular context during transformation. Perhaps EWS/FLI can also be 
used as a model to study other neural crest- or MSC-derived cancers, sarcomas, or other 
cancers of uncertain origin. 
 
Goals of the thesis 
While NKX2-2 is one of the most highly upregulated and earliest identified 
EWS/FLI transcriptional targets, we do not know its biological function in Ewing 
sarcoma. As had been discussed above, NKX2-2 is critical for transformation and the 
individual contributions of its domains to this phenotype have been elucidated. 
However, there were key unknowns as well. We therefore identified two major related 
goals for my doctoral research, which I briefly discuss here. 
The first goal of my thesis is to make biologic sense of the transcriptional 
program mediated by NKX2-2 in Ewing sarcoma. To this end, we performed NKX2-2 
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transcriptional profiling by RNA-seq and found that NKX2-2 represses genes important 
for cell adhesion and ECM organization. This became the impetus for testing whether 
NKX2-2 represses mesenchymal features of Ewing sarcoma, as EWS/FLI does. We found 
that this is indeed the case, and that Ewing sarcoma cells depleted of NKX2-2 show 
increased organization of actin stress fibers, increased FA assembly and cell spreading, 
and de-repression of the cytoskeletal and FA protein zyxin, which stabilizes actin stress 
fibers. Functionally, this translated to greater cell adhesion and faster cell migration. 
Importantly, we found that the NKX2-2 and ZEB2 transcriptional profiles are inverses of 
each other—exactly what is expected since these two programs represent 
“mesenchymalized” and “epithelialized” Ewing sarcoma cells, respectively. Lastly, we 
show that NKX2-2 expression level in tumors stratify outcome, with low expressors 
having a nearly significant decreased survival, suggesting that there is a “sweet spot” 
level of NKX2-2 expression that allows maintenance of transformation while providing 
cells with sufficient mesenchymal features that might promote establishment at distal 
sites. This work is published in Genes & Cancer and is detailed in Chapter 2. 
The second goal of my thesis is to identify the protein interaction partners of 
NKX2.2 to better understand the transcriptional mechanisms it employs. This 
information will give valuable clues on NKX2.2 function that a transcriptional profile 
would be unable to reveal. We undertook a candidate approach and identified MTG16 as 
a novel protein interaction partner of NKX2.2; the interaction domains were mapped on 
both NKX2.2 and MTG16. Details of this interaction led to the hypothesis and 
demonstration that NKX2.2 is capable of homo-oligomerization. Both the heterotypic 
and homotypic interactions map to the NKX2.2-TAD, demonstrating that this region is a 
competent protein-binding motif. This work is detailed in Chapter 3. 
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Activation of the Notch pathway is inhibitory to the proliferation of Ewing 
sarcoma cells. To investigate the possible role of NKX2.2 in this growth inhibition, we 
asked whether NKX2.2 and the Notch transcriptional switch protein MTG16 are found in 
the same repressor complex. Here we show that NKX2.2 and MTG16 participate in a 
novel protein-protein interaction. Using domain deletion mutants of both proteins, we 
mapped this interaction on the transcriptional activation domain (TAD) of NKX2.2 and 
on the PST2 and NHR2 domains of MTG16. Unexpectedly, our co-immunoprecipitation 
studies also indicated that abolishing the DNA binding property of NKX2.2 either by the 
N178Q mutation or a full homeodomain deletion allows it to bind MTG16 with a much 
higher affinity. Furthermore, we found that NKX2.2 forms a homo-oligomer the 
assembly of which is similarly TAD-dependent. Lastly, we show that Notch1 competes 
with the NKX2.2 for MTG16 binding. While low expression levels for MTG16 in Ewing 
sarcoma cells may hamper the investigation of a potential NKX2.2-MTG16-controlled 
complex during Notch-induced growth inhibition, our work proposes that functional 
binding of these two proteins is possible in the proper cellular context and may be 
tractable in a pancreatic β-islet system. Moreover, we demonstrate that the NKX2.2 TAD 
is a competent protein binding motif. Whether the heterotypic and/or homotypic TAD-
mediated interactions suppress direct transcriptional activation by NKX2.2, and whether 
different members of the NK2 and MTG families also interact, are interesting questions 
and are suggested prospects for future studies. 
 
Introduction 
NKX2.2 is a member of the evolutionarily ancient NK family of DNA-binding 
transcription factors. It has various functions that include specification of V3 
interneurons in the central nervous system, control of oligodendrocyte development, 
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specification of insulin-producing β-islet cells in the pancreas, etc. [1-15]. Like other 
members of this family, NKX2.2 harbors a homeodomain (HD), which facilitates binding 
to specific target sequences in the genome, as well as the tinman (TN) domain (Fig. 3.1). 
Functional inactivation of tin in the fly or knockout of Nkx2.5 in the mouse—orthologous 
proteins that bear the TN domain—leads to abnormal heart development and early 
embryonic death [16]. TN has been shown to effect transcriptional repression, primarily 
through recruitment of Gro/TLE co-repressors and histone deacetylases (HDACs) [17]. 
Presumably, HDACs remove activating histone acetyl marks from surrounding histones, 
leading to compaction of the local epigenetic landscape and reduced access to 
transcription factors. NKX2.2, in addition, harbors the specific domain (SD), which is 
present in other NK2 family members, and the transcriptional activation domain (TAD) 
(Fig. 3.1) [16, 18]. Using luciferase reporter assays, Watada and colleagues demonstrated 
that a full deletion of, or a double A204E/L208E mutation in, the SD unmasks a C-
terminal domain that effects transcriptional activation (i.e., the TAD) [18]. NKX2.2 and 
other NK2-class transcription factors have been shown to both transcriptionally repress 
and activate targets, though less certain is what governs switching between these two 
modes [7, 10, 11, 13, 18-20]. 
Previously it was demonstrated that activation of the Notch signaling pathway 
elicits growth inhibition in Ewing sarcoma cell lines. In particular, ectopic expression of 
the Notch ligand JAG1 or of the intracellular domains of Notch1 (N1-ICD), Notch2, or 
Notch3 in the Ewing sarcoma cell lines TC252 and SK-N-MC ablated cell proliferation 
completely [21]. It was unclear in this study whether cell growth was arrested or whether 
cells underwent necrosis or apoptosis. However, the effect of Notch activation was very 




One way that NKX2.2 can impose an effect on Notch-induced growth inhibition 
is through MTG16 (myeloid translocation gene on chromosome 16). MTG16, 
alternatively named ETO2 or CBFA2T3, itself participates in the chromosomal 
translocation t(16;21)(q24;q22) that drives acute myeloid leukemia (AML) [22]. In the 
absence of an activating signal, Notch transcriptional targets are in a repressed state: 
DNA-bound CSL recruits MTG16, co-repressors, and HDACs. Upon binding of a cognate 
ligand, sequential protease cleavages of the Notch1 receptor occur, releasing N1-ICD 
from the plasma membrane and into the nucleus, where it binds CSL, knocks off MTG16 
and associated co-repressors, and recruits mastermind-like (MAML) and co-activators. 
Thus, MTG16 serves as the switch between the repressed and activated states of Notch 
targets [23]. Using a series of co-immunoprecipitation experiments utilizing serial 
domain deletion mutants of MTG16 (Fig. 3.2), Engel and colleagues demonstrated that 
MTG16 binds CSL via the NHR3 domain and N1-ICD via the PST1 domain; importantly, 
N1-ICD was shown to disrupt the MTG16-CSL interaction [23]. Thus, we decided to 
pursue a candidate approach and investigate whether these interactions define a 
framework in which NKX2.2 and MTG16 participate in a complex that is disassembled 
by a Notch signal, leading to Ewing sarcoma growth inhibition. 
 
Results 
Previously it was shown that MTG16 serves as the switch between the repressed 
and activated states of Notch target promoters. Specifically, it was demonstrated that 
MTG16 binds N1-ICD [23]. We reasoned that NKX2.2 may participate in the same 
repressive, MTG16-harboring complex. We enforced co-expression of Flag-tagged 
NKX2.2 and myc-tagged MTG16 in HEK293-EBNA cells. Co-immunoprecipation studies 
from whole cell protein lysates revealed that NKX2.2 and MTG16 indeed physically 
interact (Fig. 3.3a). We next mapped this interaction using the domain deletion mutants 
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of NKX2.2 [24]. While deletions of TN or SD are dispensable for the interaction, any 
mutant with the TAD deleted (i.e., ΔTAD, ΔSD-TAD, and TN-HD) resulted in abrogation 
of the interaction (Fig. 3.3a). We therefore concluded that the NKX2.2-MTG16 
interaction is facilitated by the TAD. Unexpectedly, we found that the point mutant 
N178Q pulled down MTG16 with dramatically higher affinity than wild-type or indeed 
any other mutant (Fig. 3.3a). This put forward two possibilities. One, the substitution of 
asparagine with glutamine at position 178 causes a conformational change that allows 
NKX2.2 to unravel and expose the MTG16 binding surface on the TAD. We reasoned that 
this is improbable owing to the minimal structural change with that substitution. More 
likely, NKX2.2 switches between “closed” and “open” conformations depending on the 
state of DNA binding. We reasoned that a different DNA binding mutant should 
phenocopy N178Q if the second possibility is true. To this end, we cloned a full deletion 
of the homeodomain (ΔHD, Fig. 3.1). Indeed, ΔHD pulls down MTG16 with the same 
high affinity as N178Q (Fig. 3.3a). 
We next mapped the interaction on MTG16 using myc-tagged serial domain 
deletion mutants (Fig. 3.2; Fig. 3.3b,c). When we pulled down immunocomplexes using 
α-Flag and blotted for myc, all of the ΔC mutants showed an interaction, except 
MTG16Δ6C and MTG16Δ7C (Fig. 3.3b). These NKX2.2-binding-deficient mutants both lack 
the PST2 domain (Fig. 3.2), suggesting that the NKX2.2-MTG16 interaction is mediated 
by PST2. However, immunoprecipitations using the ΔN mutant series revealed that 
MTG16Δ7N, which lacks the PST2 domain, is capable of binding, while MTG16Δ8N, which 
lacks the contiguous PST2 and NHR2 domains, is not (Fig. 3.2; Fig. 3.3c). If PST2 is the 
lone mediator of NKX2.2 binding, we would predict that MTG16Δ7N abolishes the 
interaction. Therefore, it appears that PST2 and NHR2 comprise an interface to which 
NKX2.2 binds. This model is consistent with both MTG16Δ5C and MTG16Δ7N being 
capable of NKX2.2 binding (Fig. 3.2; Fig. 3.3b,c). MTG16 mutants with smaller deletions 
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at or near the PST2-NHR2 boundary may help define the minimal region able to bind 
NKX2.2, and is an interesting aim for future studies. 
 Another prediction from these data is that the HD somehow occludes the MTG16 
binding surface on the TAD; this model is consistent with the higher MTG16 affinity of 
N178Q and ΔHD compared to wild-type NKX2.2. One mechanism by which this might 
occur is if NKX2.2 binds itself. We therefore sought to determine whether NKX2.2 
oligomerization occurs. To this end we cloned the wild-type and mutant constructs of 
NKX2.2 to express an N-terminal hemagglutinin (HA) tag (Fig. 3.1). We co-expressed 
3xFlag::NKX2.2 and HA::NKX2.2 in HEK293-EBNA cells and isolated protein. Using 
these whole cell lysates, we again pulled down with α-Flag and blotted with HA. Indeed, 
we observed that the differently tagged species of NKX2.2 interact with each other, 
demonstrating oligomerization (Fig. 3.4a). To map this interaction, we co-expressed 
3xFlag::NKX2.2 and either wild-type or mutant HA::NKX2.2. Interestingly, the TAD 
again is indispensable for this homotypic interaction (Fig. 3.4a). To ensure that the result 
is not an artifact, we imposed the expression of 3xFlag::ΔTAD against the full 
complement of HA-tagged constructs. Expectedly, when we pulled down 
immunocomplexes with α-Flag, none of the HA constructs indicated any interaction 
(Fig. 3.4b). We therefore concluded that the TAD facilitates homo-oligomerization of 
NKX2.2. Interestingly, mouse Nkx2.5 has been previously demonstrated to form dimers 
both on and off DNA, and to contact proximal palindromic binding sites in the promoter 
of the atrial natriuretic factor (ANF) gene, a known direct target. It was demonstrated 
that regions in both the HD and in the C-terminal domain (i.e., parallel to the NKX2.2-
TAD) are required for homodimerization on DNA [25]. Subsequent studies elucidated 
the crystal structure of the Nkx2.5-HD bound to the ANF promoter and, while only the 
HD and not the full-length protein was crystallized, the authors posit that such a 
conformation would allow the C-termini of two Nkx2.5 molecules to physically interact 
53 
 
and form a dimer [26]. This is consistent with our observation that the TAD, which is the 
most C-terminal domain of NKX2.2, is absolutely required for homo-oligomerization. 
Whether NKX2.2 in Ewing sarcoma cells forms a dimer or has more component 
subunits, and whether the homo-oligomeric form is DNA-bound, are yet to be 
determined. It is worthwhile to note that the NHR2 domain of MTG16 and of the related 
MTG8 and MTGR1 proteins facilitates homotetramerization [27]. 
We next explored the possibility that N1-ICD disrupts the NKX2.2-MTG16 
complex, in a manner parallel to its disruption of the MTG16-CSL complex [23]. To 
address this question, we imposed the expression of increasing levels of N1-ICD on the 
NKX2.2-MTG16 interaction. We expected to see that the NKX2.2-MTG16 interaction 
would dose-dependently decrease with increasing N1-ICD expression, and this is indeed 
the case (Fig. 3.5a). Importantly, MTG16Δ2N—which lacks the PST1 domain that mediates 
N1-ICD binding—is incapable of disrupting the NKX2.2-MTG16 complex (Fig. 3.2; Fig. 
3.5a) [23]. This suggests that it is specifically the binding of N1-ICD to MTG16 that 
knocks NKX2.2 off the complex. 
 
Discussion 
Concurrent experiments at the time indicated that expression levels of MTG16, 
MTG8, and MTGR1 are very low in A673 cells and other Ewing sarcoma cell lines (data 
not shown and ref. [28]). This does not necessarily preclude the assembly of an NKX2.2-
MTG6-controlled repressor complex in our system of interest, but we surmise that its 
experimental confirmation will be technically very difficult. However, there is a 
possibility that such a complex forms and is functional in a pancreatic β-islet system. We 
have preliminary evidence that MTG16 is expressed and is amenable to 
immunoprecipitation in βTC6 cells, a murine pancreatic insulinoma cell line derived 
from β-islet cells (Fig. 3.5b). NKX2.2 is also expressed in these cells [13], giving rise to 
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the question of whether an endogenous NKX2.2-MTG16 complex exists in this system. If 
such a complex does exist and is stable, the question of the biological significance of the 
NKX2.2-MTG16 interaction—the biggest gap in our current work—can finally be 
addressed. We have identified many lines of investigation stemming from our data. In 
particular, does NKX2.2-MTG16 recruit Gro/TLE co-repressors and HDACs at 
previously identified NKX2.2 direct transcriptional targets in β-islet cells? Is repression 
mediated through changes in the local epigenetic landscape? Does Notch activation 
figure in β-islet cell specification? Importantly, β-islet cells may serve as a paradigm in 
which to further investigate the role NKX2.2 in mediating cell specification and 
differentiation, as has been shown in various contexts [2, 4, 5, 9, 10, 13, 15, 28]. 
Although at this time we have not worked out the biological significance of the 
NKX2.2-MTG16 interaction, our current work makes significant contributions to the 
understanding of protein interactions mediated by NKX2.2. Firstly, to the best of our 
knowledge, the interaction of NKX2.2 and MTG16 has not been reported before. MTG16 
is a scaffolding protein that has numerous protein binding interfaces. The possibility that 
NKX2.2 recruits MTG16 to amplify its ability to recruit co-repressors to DNA and cause 
direct transcriptional repression is very interesting and needs to be experimentally 
validated. The elucidation of biochemical and stoichiometric details is also vastly 
important. We need to answer whether the NKX2.2-MTG16 interaction is direct or 
mediated by other proteins, and how many NKX2.2 and MTG16 subunits are assembled 
on promoters for transcriptional repression. 
Secondly, we discovered that NKX2.2 is able to oligomerize with itself—another 
novel interaction. This is consistent with reports of the related mouse protein Nkx2.5 
forming DNA-bound dimers [25, 26]. The finding brings forth many interesting 
questions, such as whether these NKX2.2 oligomers are DNA-bound. More pointedly, is 
oligomerization a mechanism by which NKX2.2 activity can be regulated post-
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translationally? Because this is a homotypic interaction, one could potentially ask these 
questions in any cellular context wherein NKX2.2 is expressed: Ewing sarcoma, β-islet 
cells, or developing interneurons and oligodendrocytes.  
Thirdly, we have demonstrated that the TAD is a competent protein-binding 
motif, both in heterotypic and homotypic interactions. Interestingly, the mouse Nkx2.5 
dimer previously identified also forms contacts partly via the C-terminal domain, which 
is the TAD in NKX2.2. However, we have not asked specifically whether the HD 
contributes to NKX2.2 homo-oligomerization, as it does in Nkx2.5 dimers [25, 26]. In 
addition, our data bring forth the possibility that proteins binding to TAD may suppress 
direct transcriptional activation by NKX2.2, and may help explain why deletion of SD 
allows activation to occur [18]. Furthermore, since both mouse Nkx2.5 and human 
NKX2.2 form oligomers, we hypothesize that this is a generalizable feature of NK2 class 
transcription factors. Taking this hypothesis further, and considering that TAD mediates 
heterotypic interactions as well and that the MTG proteins are very structurally similar, 
one might predict that any TAD-bearing NK2-class transcription factor and MTG family 
member may possibly interact. In summary, our current study identifies novel protein-
protein interactions of NKX2.2, presents preliminary data that such interactions are 
possible and functional in other cellular contexts, and proposes future aims for the 
investigation of the biological significance of NKX2.2 binding with MTG16 and homo-
oligomerization. 
 
Materials and Methods 
Cloning of cDNA constructs 
The cloning strategies for myc::MTG16 (pCMV5), serial domain deletion mutants 
of MTG16 from either the N- or C-terminus, and Flag::N1-ICD (pCMV5) have been 
previously described [23]. The cloning strategies for 3xFlag::NKX2.2 (pQCXIN) and 
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domain deletion mutants of NKX2.2 have also been previously described [24]. Briefly, 
the 3xFlag::ΔHD-NKX2.2 (pQCXIN) was generated using a two-step sewing PCR with 







PCR products were visualized using ethidium bromide on 1% agarose, then the 
expected amplicons were excised and gel-purified using a QIAquick Gel Extraction Kit 
(Qiagen). The amplicons and pQCXIN were NotI- and BamHI-restricted and ligated with 
T4 DNA ligase (New England Biosciences). Using standard techniques, ligation products 
were used to transform chemically competent DH5α E. coli, clones were tested for the 
cDNA in correct orientation, and DNA sequence was confirmed.  The HA-tagged wild-
type and domain deletion NKX2.2 constructs were PCR-amplified from their Flag-tagged 







Amplicons were purified and subcloned into NotI- and BamHI-restricted pQCXIH 




Cell line and transfections 
HEK293 cells expressing the Epstein-Barr virus nuclear antigen (EBNA) were 
grown in neomycin selection using standard techniques. The day before transfection, 1 x 
107 HEK293-EBNA cells were seeded into 10-cm tissue culture dishes. The transfection 
cocktail consisted of: 10 μg of each construct, 30 μL TransIT-LT1 Transfection Reagent 
(Mirus) per 10 μg DNA, and 2 mL Opti-MEM I Reduced Serum Medium (Life 
Technologies). The transfection cocktail was mixed by inverting and left to incubate at 
room temperature for 20 min. The nutrient media from the cells was aspirated and 
replaced with 3 mL of the following media: 10% fetal bovine serum (Life Technologies), 
1% penicillin-streptomycin-glutamine (Life Technologies), and 100 μM sodium pyruvate 
(Life Technologies) in Dulbecco's Modified Eagle's Medium (Corning). The transfection 
mix was pipetted dropwise into the dish and left to incubate at 37°C and 5% CO2 for 48 h. 
 
Co-Immunoprecipitation 
After incubation, the media was aspirated. Working quickly on ice, cells were 
washed twice with ice-cold PBS and harvested using a cell lifter. Cells were resuspended 
in 1 mL phosphoprotecting lysis buffer (PPLB) with protease inhibitors added 
immediately before lysis, and transferred to chilled 1.5-mL microcentrifuge tubes. The 
cell suspension was sonicated on ice for 20 s (10 cycles of 1 s “on” and 1 s “off”) at 5 W 
using a Misonix Sonicator 3000 fitted with a microtip probe, then rotated for 30 min at 
4°C. Total cell protein lysates were centrifuged at 13000 rpm for 30 min at 4°C. Clarified 
extracts were transferred to fresh tubes. A 75-μL aliquot was reserved and resuspended 
with an equal volume of 2x SDS gel loading buffer with DTT. The protein lysates were 
pre-cleared with 30 μL of sheep anti-mouse IgG Dynabeads M-280 (Life Technologies) 
for 1 h at 4°C with rotation. The beads were collected using a magnetic tube rack, then 
the lysates were transferred to tubes contaning 3 μg mouse α-Flag M2 antibody (Sigma). 
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The tubes were rotated for 5 min at 4°C to distribute the antibody, then incubated on ice 
in the cold room for 90 min. The immunocomplexes were precipitated with 30 μL of 
sheep α-mouse IgG Dynabeads for 1 h at 4°C with rotation. Beads were collected and the 
supernatants disposed. Beads were washed three times with 750 μL PPLB without 
protease inhibitors, each time for 2 min at 4°C with rotation. Beads were collected and 
and resuspended in 65 μL 2x SDS gel loading buffer, boiled for 10 min, and stored at -
80°C or prepared for western blotting. This protocol was adapted from [23]. 
 
Antibodies and western blotting 
 Western blotting was performed using standard techniques. We used the 
following commercially available primary antibodies: rabbit anti-HA (Abcam) and 
mouse α-tubulin (Calbiochem). The R332 and R333 rabbit α -MTG16 antibodies were 
kind gifts from Michael Engel. We used the following HRP-conjugated secondary 
antibodies: mouse α-Flag M2 (Sigma), donkey α-rabbit IgG (GE Healthcare), sheep α-









Figure 3.1. Domain organization of wild-type and mutant human NKX2.2. 
The functional domains tinman (TN), homeodomain (HD), specific domain (SD), and 
transcriptional activation domain (TAD), as well as linker regions, are drawn to scale 
from the N to the C terminus. For illustration purposes, the linker between TN and HD is 
drawn at a quarter of its length. The DNA binding point mutant N178Q is indicated in 
magenta. Small vertical bars in cyan indicate a domain deletion between flanking linkers. 








Figure 3.2. Domain organization of wild-type and mutant mouse MTG16. 
The three PST (P) and four NHR (N) domains, as well as linker regions, are drawn to 
scale. ΔC and ΔN mutants are successive deletions from the C or N terminus, 
respectively. The N-terminal myc tag is not illustrated. The exact boundaries of the 






























Figure 3.3. NKX2.2 and MTG16 participate in a novel protein interaction 
that is mappable on both proteins. 
(a) NKX2.2 and MTG16 bind using a co-immunoprecipitation assay in a TAD-dependent 
fashion. Wild-type or mutant 3xFlag::NKX2.2 or empty pQCXIN vector and 
myc::MTG16 or empty pCMV5 vector were used to transfect HEK293-EBNA cells, as 
indicated. Whole cell lysates (input) or immunocomplexes precipitated with α-Flag 
antibody were run in SDS-PAGE and blotted for MTG16 (R333), Flag, or tubulin. The 
asterisk denotes the high MW species of each NKX2.2 variant. (b,c) The NKX2.2-MTG16 
interaction requires the PST2 domain of MTG16. Expression of 3xFlag::NKX2.2 was 
imposed on wild-type or mutant myc::MTG16 or empty pCMV5 vector. Input or 
immunocomplexes precipitated with α-Flag antibody were run in SDS-PAGE and blotted 
for myc, Flag, GFP, or tubulin. Shown are co-immunoprecipitation mapping experiments 








Figure 3.4. NKX2.2 forms a homo-oligomer using TAD. 
(a) NKX2.2 forms a TAD-dependent homo-oligomer. Differently tagged species of wild-
type or mutant NKX2.2 (HA-tag in pQCXIH, 3xFlag-tag in pQCXIN) or empty vector 
were used to transfect HEK293-EBNA cells, as indicated. Co-immunoprecipitations are 
as in Fig. 3.3a. The asterisk denotes the high MW species of each NKX2.2 variant. (b) 
TAD deletion abrogates homo-oligomerization. HA::ΔTAD expression was imposed on 
wild-type or mutant 3xFlag::NKX2.2. Co-immunoprecipitations are as in Fig. 3.3a. The 







Figure 3.5. NKX2.2 and Notch1 intracellular domain compete for MTG16 
binding. 
(a) Expression of increasing levels of the Flag::N1-ICD construct was imposed upon 
constant levels of 3xFlag::NKX2.2 and either myc::MTG16 or myc::MTG16Δ2N. Input or 
immunocomplexes precipitated with α-Flag antibody were run in SDS-PAGE and blotted 
for Flag, myc, or tubulin. The asterisk denotes the high MW species of NKX2.2. (b) 
MTG16 is expressed and is amenable to immunoprecipitation in murine βTC6 cells. 
Shown are 5% input whole cell lysate and rabbit IgG- or α-MTG16 (R332)-
immunoprecipitated complexes blotted with a different α-MTG16 antibody (R333). The 
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The work presented in this doctoral dissertation represents a logical and 
necessary continuity in the work of our laboratory on the function of NKX2-2 in Ewing 
sarcoma. Previously, our group identified NKX2.2 as a critical upregulated gene in Ewing 
sarcoma and demonstrated that it is a distinguishing marker for this pediatric cancer 
among look-alike SRBCTs [1]. Furthermore, it was demonstrated that transcriptional 
repression, DNA binding, and suppression of transcriptional activation were functions 
that were necessary for NKX2-2 to maintain the transformed phenotype. Through 
microarray transcriptional profiling, it was shown that NKX2-2 mediates a significant 
portion of the EWS/FLI-regulated universe of transcriptional targets, and that the pan-
HDAC inhibitor vorinostat fully reverses the NKX2-2 program, suggesting that histone 
deacetylation is a chief mechanism by which NKX2-2 regulates its targets [2]. 
In this current work, we took two separate but related approaches to fully define 
the role of NKX2-2 in Ewing sarcomagenesis. In the first approach, detailed in Chapter 2 
[3], we performed NKX2-2 transcriptional profiling in the Ewing sarcoma cell line A673 
using RNA-seq, both to overcome the biases of microarrays and to facilitate direct 
comparisons with other deep sequencing efforts in our lab. What we found was 
extremely interesting: NKX2-2 represses genes critical for cell adhesion and ECM 
organization. Through immunofluorescence studies, cell adhesion and migration assays, 
and assessment of zyxin levels, we demonstrated that, much like EWS/FLI depletion [4, 
5], NKX2-2 loss imbues Ewing sarcoma cells with mesenchymal characteristics. 
Importantly, we found that NKX2-2 and ZEB2 control anti-mesenchymalization and 
anti-epithelialization programs, respectively, in this cancer [3]. 
This finding mirrors some of the identified roles of NKX2.2, especially with 
respect to developmental arrest and differentiation. For example, NKX2.2 binds and 
represses the promoter of Arx in mouse βTC6 cells. If the NKX2.2-TN repressor domain 




cell-specific factors and increased expression of α-cell-specific factors, suggesting β- to α-
cell reprogramming. The effect is completely neutralized by deleting Arx, suggesting that 
re-differentiation is dependent upon NKX2-2 repression of this gene [6]. In a similar 
fashion, deletion of Nkx2.2 in mice generates somatic motor neurons where V3 
interneurons should have developed. This ventral expansion suggests that V3 progenitor 
cells have the capacity for motor neuron development that is inhibited by Nkx2.2 
expression [7]. In gliomas, it has been demonstrated that decreasing NKX2-2 levels is 
correlated with cancer progression. In particular, NKX2-2 inhibits the self-renewal 
ability of glioma-initiating cells by promoting oligodendroglial differentiation [8]. This is 
in contrast with the role of NKX2-2 in Ewing sarcoma, wherein it inhibits differentiation; 
nonetheless, in either case, weak levels of NKX2-2 seem to promote tumor progression, 
echoing the importance of cellular context in carcinogenesis. 
There are many questions left unanswered. First, we need to define the direct 
transcriptional targets of NKX2-2. We have attempted this before using two chromatin 
immunoprecipitation (ChIP)-based strategies: an endogenous ChIP using a NKX2.2-
specific antibody and streptavidin ChIP using biotinylated, exogenous NKX2.2. While I 
can show in either strategy that endogenous or exogenous NKX2.2 can be pulled down 
efficiently and specifically, our RNA-seq data revealed no bona fide targets. One 
difficulty is the absence of confirmed direct NKX2.2 targets in Ewing sarcoma that could 
serve as positive controls during optimization. The consensus sequence of NKX2.2, 
T(T/C)AAGT(A/G)(C/G)TT, determined using a PCR-based enrichment strategy [9], was 
confirmed by our group to be bound in vitro by all our NKX2.2 constructs (Fig. 3.1), 
except the DNA-binding mutant N178Q [2]. Through bioinformatic analysis of protein-
binding microarrays and electrophoretic mobility shift assays, a binding site containing 
an alternative “GAGT” core (instead of “AAGT”) was also predicted and confirmed [10]. 




identified NKX2-2-regulated targets for these consensus sites to find candidate genes for 
positive controls. Finding the direct target loci of NKX2.2 in Ewing sarcoma will allow us 
to ask many questions: does NKX2.2 recruit Gro/TLE co-repressors and HDACs to these 
regions and alter histone acetylation marks, as has been previously demonstrated in a 
pancreatic β-islet cell line [6]? Does ΔSD or a potential double deletion ΔTN-ΔSD drive 
transcriptional activation of an otherwise repressed target gene? Furthermore, it would 
be interesting to ascertain whether any of the repressed ECM genes, such as several 
collagen subtypes, identified by RNA-seq are direct targets. While we have demonstrated 
the importance of cell adhesion to the repressed mesenchymal program in Ewing 
sarcoma cells, we have not directly addressed the significance of repressing ECM 
organization. Interestingly, while Ewing sarcoma SK-ES-1 cells adhered to fibronectin or 
laminin substrates [11], they did not adhere to substrates supplemented with collagen I, 
III, or IV [12]. We need to confirm this in a panel of Ewing cell lines and ask whether de-
repression of collagen genes affects adhesion and, possibly, transformation and 
metastasis. Importantly, the composition of the surrounding ECM might play a role in 
distal site “decision-making” during the metastatic process. Lastly, since the 
stratification of patient survival using NKX2-2 expression levels only approached 
significance (p=0.07; Fig. 2.7), we need to survey other available datasets to see whether 
this trend holds. 
One prediction that could be made from the quantified immunofluorescence data 
is that, because we make our observations on polyclonal populations of shRNA-infected 
cells, the specific level of NKX2-2 or EWS/FLI in a particular cell dictates how 
“mesenchymalized” that cell is. Since lower NKX2-2 expression levels in tumors indicate 
a poor prognosis (Fig. 2.7), our in vitro data may have repercussions on patient survival. 
An interesting route of investigation is to perform single-cell RNA-seq from Ewing 




respect to NKX2-2 expression, and perhaps shed light on what percentage of the tumor 
has an enhanced capacity to escape and migrate at baseline. 
A possibility that has previously been suggested is that Ewing sarcoma cells may 
toggle expression of EWS/FLI and/or ZEB2 to accentuate mesenchymal or epithelial 
traits [13]. I propose here that NKX2-2 levels might also be toggled through EWS/FLI to 
drive transient re-differentiation into a cell type with manifest mesenchymal 
characteristics and to promote migration to a distal site. To investigate this, different 
fluorescent reporters may be engineered, through CRISPR-Cas9, into the endogenous 
NKX2-2 and ZEB2 loci. In this way, Ewing sarcoma cells xenografted into mice using the 
intratibial model may be monitored as they form the primary tumor, travel through the 
bloodstream, and establish a secondary site. The challenge here is catching the Ewing 
sarcoma cells during transit. While there is evidence that EWS/FLI induces CD99 
expression, this seems to be a weak regulation [14]. Perhaps migrating Ewing sarcoma 
cells can be captured in the bloodstream using CD99, and the ratio of NKX2-2 to ZEB2 
expression (i.e., fluorescence) may serve as the readout for whether the cell is more 
mesenchymal or more epithelial. 
In the second part of my dissertation, with the understanding that NKX2-2 
depends on other factors to perform its transcriptional roles, we asked who the NKX2.2 
interaction partners are. Though not described in this manuscript, we addressed this 
question using an unbiased strategy. I expressed the abovementioned biotinylated 
3xFlag::NKX2.2 construct in Ewing sarcoma A673 cells and performed tandem affinity 
purification, first with streptavidin, then with a Flag antibody [15]. Our mass 
spectrometry experiment did not identify any Gro/TLE family proteins or HDACs—
protein interaction partners that we were expecting to see. As a result, we undertook a 
candidate approach that involved MTG16; the work comprises Chapter 3 of this 




with MTG16, and NKX2.2 with itself. Both binding events are facilitated by the NKX2.2-
TAD, suggesting that this domain is a competent protein-binding motif. While low 
expression levels of MTG16 prevented our further investigation of this complex in Ewing 
sarcoma cells, we and other groups demonstrated that NKX2.2 [6] and MTG16 (Fig. 3.5) 
are expressed at sufficient levels and are amenable to immunoprecipitation in βTC6 
cells. 
 It has been previously suggested that pancreatic differentiation borrows many 
aspects of neural development, despite these two tissues originating from different germ 
layers (endoderm and ectoderm, respectively). The pancreas and the brain overlap 
significantly in many aspects, such as cellular physiology, gene expression, and 
modulation by the same transcription factors [16]. The demonstration that one such 
transcription factor, NKX2.2, has the capacity to interact with novel proteins through its 
TAD might allow us to ask broader questions about development and evolution. A 
possible future experiment might be to use the NKX2.2-TAD as a bait to identify protein 
interaction partners in Ewing sarcoma, developing β-islet cells, and neural progenitors. 
Are there any similarities in the interactomes of these different cell types? Do different 
TAD-harboring NK2 factors pull down different proteins? Surveying the interactions of 
proteins that co-evolved to function in the same complexes and pathways may give 
information that is as critical as defining the epistatic relationships of transcription 
factors and their targets. It is tempting to speculate that the developmental role of 
NKX2-2 in Ewing sarcoma might give clues to the function of a possible NKX2.2-
controlled complex in the development of other tissues, such as the pancreas. 
 Unquestionably, the way forward is to be able to target Ewing sarcoma cells 
effectively and specifically. A small molecule inhibitor of LSD1, HCI2509, was developed 
in the laboratory of Sunil Sharma in collaboration with our group here at the Huntsman 




profile of EWS/FLI knockdown. Moreover, HCI2509 reduces colony formation in soft 
agar, increases caspase activity, and reduces the volume of tumor xenografts in nude 
mice, leading to greater survival [17]. Interestingly, treatment with the LSD1 inhibitor 
also causes Ewing sarcoma cells to display mesenchymal features in a dose-dependent 
manner. The cells do eventually die, presumably from blockage of LSD1-dependent 
EWS/FLI function [17]. It will be critical to ensure that, in the timeframe between the 
cells manifesting mesenchymal characteristics and cell death, Ewing sarcoma cells do 
not gain sufficient migratory capabilities to allow for tumor escape, transit, and 
establishment of a viable metastatic site. Perhaps a strategy to simultaneously target 
tumor cells with HCI2509 and with the miR-200 cluster to both inhibit LSD1 function 
and promote epithelialization through downregulation of ZEB2, respectively, may prove 
to be therapeutically useful. Importantly, our studies of the transcription factors 
EWS/FLI, ZEB2, and NKX2-2 have helped us understand the plasticity of Ewing 
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